Chimerix (CMRX)
(Real Time Quote from BATS)
$0.82 USD
0.00 (-0.01%)
Updated Aug 12, 2024 01:30 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Brokerage Reports
Chimerix, Inc. [CMRX]
Reports for Purchase
Showing records 81 - 100 ( 116 total )
Company: Chimerix, Inc.
Industry: Medical - Products
1Q21 Results; Brincidofovir PDUFA July 7; Raising PT by $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Initiating at OUTPERFORM; The Value Is Not a Chimera, Buy CMRX
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Chimerix, Inc.
Industry: Medical - Products
BARDA Issues SSN for Smallpox Antivirals, the First Step in the RFP Process
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
4Q20 Results; Strong Data From DSTAT in COVID-19 Trial Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Another Impressive Acquisition Announced; Raising PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
FDA Accepts NDA for Brincidofovir in Smallpox; PDUFA Date of April 7, 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
FDA Accepts NDA for Brincidofovir in Smallpox; PDUFA Date of April 7, 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
3Q20 Results; BCV in Smallpox Rolling NDA Submission Completed
Provider: H.C. Wainwright & Co., Inc.
Analyst: WRIGHT J
Company: Chimerix, Inc.
Industry: Medical - Products
2Q20 Results; Rolling NDA for BCV in Small Pox to Complete This Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
1Q20 Results; Catalysts in AML, COVID-19 and Smallpox in 2H20
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Chimerix Keeps Busy During the Pandemic With COVID-19
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Brincidofovir Receives FDA Clearance for Rolling Submission of NDA for Smallpox
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
4Q19 Results; DSTAT Phase 3 Study to Commence in Mid-2020; BCV NDA Submission Expected 2H20
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Brincidofovir Smallpox Data Presented at the 2020 American Society for Microbiology Biothreats Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
3Q19 Results; BCV NDA Filing for Smallpox Expected Mid-2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Brincidofovir Exclusive Global Licensing Agreement With SymBio Pharmaceuticals Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
2Q19 Results; Phase 3 CX-01 Trial Data in AML Possible Mid-2020; BCV NDA for Small Pox Filing Expected in 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E